HOME
PDF DOWNLOAD
PLAY LIST
Presentation file(PDF 986 KB)
from the beginning
Acquisition of Tolero Pharmaceuticals, Inc.
Acquisition of Tolero Pharmaceuticals, Inc.
Tolero’s Development Products and Discovery Capabilities
Profile of Alvocidib
Phase 2 Study Results of Alvocidib (efficacy) (Conducted by NCI)
Phase 2 Study Results of Alvocidib (safety) (Conducted by NCI)
Clinical Development Plan of Alvocidib
Phase 2 Study Design of Alvocidib (Biomarker)
Rate of Patients with High MCL-1 Expression
Profile of TP-0903
Profile of TP-0184
Transaction Summary and Financial Impact
R&D System of Oncology Area after Deal Closing
Results of Past Clinical Studies of alvocidib (AML)
(slide only)
AML Treatment Methods
(slide only)
Disclaimer Regarding Forward-looking Statements
(slide only)
@@@
Q&A
Q&A1
Q&A2
Q&A3
Q&A4
Q&A5
Q&A6
Q&A7
Q&A8
Q&A9
December 21, 2016
Sumitomo Dainippon Pharma Co., Ltd.
Acquisition of Tolero Pharmaceuticals, Inc.
1
/27
